Research
In phase 2 trial, novel therapy significantly reduced triglyceride levels
The Brief
- A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers tested MAR001, a monoclonal antibody therapy.
- The trial found MAR001 significantly reduced triglyceride levels within 12 weeks in patients with high triglyceride levels.
Why it matters
It reports early clinical evidence for a new antibody-based way to lower triglycerides, a lipid linked to cardiovascular risk, though it is a phase 2 result and not yet an approved treatment.
Who’s affected
- patients with high triglyceride levels
- cardiologists and lipid researchers
- pharmaceutical developers working on lipid-lowering therapies
- #triglycerides
- #monoclonal antibody
- #clinical trial
- #cardiovascular
- #lipids
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are…